ITS develops a new T-cell vaccine to protect humans from seasonal and pandemic influenza A

ITS develops a new T-cell vaccine to protect humans from seasonal and pandemic influenza A -

Immune Targeting Systems (ITS), specializing in the development of immune therapies novel T cell, has been the development of a new vaccine T cells exciting (Flunisyn ^TM ) to protect humans from all seasonal influenza strains and pandemic A. to determine effectiveness Flunisyn of ^TM STI produces its own living influenza challenge agent derived from influenza A / California / 09 (H1N1) virus circulating recently. This challenge virus, manufactured in compliance with the high level of quality and characterization required by the FDA of the United States and other regulatory agencies, has a much better profile infectivity reported for similar challenge virus. While the primary objective in the development of its own challenge virus was to advance the development of Flunisyn ^TM and to better understand the natural history of the disease influenza, needs to make the virus available to enable and support the development of new antiviral drugs and vaccines.

Immune Targeting Systems today announced an asset purchase agreement with Global WCCT (WCCTG) for ITS "exclusive strain developed challenge. Through this partnership, WCCTG became the only commercial company offering sponsors the opportunity to challenge studies Flu widespread in the United States. The Experimental human viral challenge model has been widely accepted as an alternative to traditional field testing at an early stage to show the efficacy of antiviral treatments and vaccines. The WCCTG facility in Costa Mesa, California, has been completely redesigned to provide private rooms, separate ventilation and other standard containment measures to receive this valuable research model and to ensure the safety and comfort of volunteers and staff.

Benjamin Chen, PhD, CEO of Immune Targeting Systems said, "We are delighted that World WCCT took over ownership of this important clinical tool for research and we are confident they will use the virus . to help support the development of new vaccines and antiviral drugs "Kenneth Kim, MD, CEO of global WCCT said:" the ability to realize the challenge model of experimental influenza in collaboration with our deep expertise in developing anti-viral drugs will surely be of great interest to our sponsors. This new capability combined with our global full service capabilities, specialized project teams of flu, and in-depth scientific knowledge allows WCCTG manage vaccination programs and antiviral development First in Man by the NDA submission. "

More on Immune targeting Systems

Immune targeting Systems, Ltd. develops T cell vaccines at highly mutated viruses and cancers. The main product Flunisyn Company ™ vaccine has been shown in three clinical studies to stimulate the production of T cells that recognize and destroy cells infected with influenza. Flunisyn ™ is a pan-influenza A vaccine applicable to multiple strains of flu without needing to be re-manufactured for each influenza season or a pandemic. The Company is also developing two other product candidates: a therapeutic vaccine against Hepatitis B for chronic hepatitis B and a vaccine against cancer for solid tumors. ITS is supported by the Novartis Venture Fund, Truffle Capital, HealthCap, Esperante Ventures Finance and large SMEs.